Myocarditis Pipeline Report 2016 - Review of CEL-SCI Corporation & GlaxoSmithKline Plc - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Myocarditis - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Myocarditis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocarditis and special features on late-stage and discontinued projects.

The report enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.

Key Topics Covered:

1. Introduction
2. Myocarditis Overview
3. Therapeutics Development
4. Pipeline Products for Myocarditis - Overview
5. Pipeline Products for Myocarditis - Comparative Analysis
6. Myocarditis - Therapeutics under Development by Companies
7. Myocarditis - Therapeutics under Investigation by Universities/Institutes
8. Myocarditis Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Myocarditis - Products under Development by Companies
13. Myocarditis - Products under Investigation by Universities/Institutes
14. Myocarditis - Companies Involved in Therapeutics Development

• CEL-SCI Corporation
• GlaxoSmithKline Plc

For more information visit http://www.researchandmarkets.com/research/swb3dq/myocarditis